2 Information about mavacamten

Marketing authorisation indication

2.1 Mavacamten (Camzyos, Bristol-Myers Squibb) is indicated for 'the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for mavacamten.


2.3 Mavacamten has a list price of £1,073.20 per pack of 28 2.5-mg, 5-mg, 10-mg or 15-mg capsules (company submission).

2.4 The company has a commercial arrangement. This makes mavacamten available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.